NASDAQ:VACC Vaccitech (VACC) Stock Price, News & Analysis → How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad) Free VACC Stock Alerts $2.50 +0.07 (+2.88%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.40▼$2.6050-Day Range$2.33▼$3.6752-Week Range$1.64▼$5.10Volume6,864 shsAverage Volume244,643 shsMarket Capitalization$96.37 millionP/E RatioN/ADividend YieldN/APrice Target$7.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Vaccitech alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Vaccitech Stock (NASDAQ:VACC)Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Read More VACC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VACC Stock News HeadlinesApril 19, 2024 | markets.businessinsider.comBuy Rating on Barinthus Biotherapeutics Backed by Promising Clinical Trials and Strong Valuation ProspectsApril 17, 2024 | americanbankingnews.comVaccitech (NASDAQ:VACC) Trading Down 4.2%April 27, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 6, 2024 | msn.comLondon is a bad place to raise money, says life sciences tsar Sir John BellMarch 2, 2024 | seekingalpha.comArbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call TranscriptJanuary 8, 2024 | markets.businessinsider.comPositive Clinical Outlook and Strong Capital Position Justify Buy Rating for Barinthus BiotherapeuticsJanuary 8, 2024 | finanznachrichten.deBarinthus Biotherapeutics: Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesJanuary 5, 2024 | finance.yahoo.comBarinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesApril 27, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.December 22, 2023 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics: Promising Pipeline and Strategic Partnerships Signal Investment OpportunityDecember 21, 2023 | markets.businessinsider.comBarinthus Biotherapeutics Collaborates With CEPI And University Of Oxford For New MERS VaccineDecember 21, 2023 | finance.yahoo.comNew partnership aims to advance vaccine against MERS coronavirusDecember 13, 2023 | finance.yahoo.comInfluenza Vaccine Market to grow by USD 2.93 billion from 2022 to 2027; North America to account for 54% of market growth - TechnavioNovember 28, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Barinthus Biotherapeutics (BRNS), Anavex Life Sciences (AVXL)November 15, 2023 | finance.yahoo.comBarinthus Biotherapeutics plc (BRNS)November 9, 2023 | finance.yahoo.comBarinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNovember 8, 2023 | money.usnews.comBarinthus Biotherapeutics Plc. - ADRNovember 7, 2023 | msn.comBarinthus stock falls 18%, day after changing name from VaccitechNovember 6, 2023 | msn.comVaccitech rebrands as Barinthus, plans to present data at AASLD meetingNovember 6, 2023 | finance.yahoo.comVaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and CancerSeptember 28, 2023 | seekingalpha.comSIRI, EC and PBTS among pre-market losersSeptember 26, 2023 | 247wallst.comMorgan Stanley Downgrades VaccitechSeptember 26, 2023 | uk.finance.yahoo.comInnovative Therapeutic Cancer Vaccines Drive Unprecedented Growth in Global Cancer Vaccines Market to 2028September 26, 2023 | seekingalpha.comVaccitech surges despite Morgan Stanley downgradeSeptember 26, 2023 | finance.yahoo.comVaccitech plc (NASDAQ:VACC) surges 85%; individual investors who own 44% shares profited along with institutionsSeptember 25, 2023 | benzinga.comGlobal Cancer Vaccines Market to Skyrocket, Projected to Reach $12.1 Billion by 2028September 25, 2023 | marketwatch.comHealth Care Up on Defensive Bets -- Health Care RoundupSee More Headlines Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VACC CUSIPN/A CIK1828185 Webwww.vaccitech.co.uk Phone44-18-6581-8808FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$7.63 High Stock Price Target$12.00 Low Stock Price Target$3.25 Potential Upside/Downside+205.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.34 million Net Margins-409.18% Pretax Margin-442.00% Return on Equity-23.41% Return on Assets-20.85% Debt Debt-to-Equity RatioN/A Current Ratio15.26 Quick Ratio15.26 Sales & Book Value Annual Sales$13.42 million Price / Sales7.18 Cash Flow$0.13 per share Price / Cash Flow19.30 Book Value$6.52 per share Price / Book0.38Miscellaneous Outstanding Shares38,547,000Free Float36,234,000Market Cap$96.37 million OptionableNot Optionable Beta-0.40 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. William J. Enright MBA (Age 60)CEO & Director Comp: $916.62kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma Brown (Age 33)CFO & Company Secretary Mr. Chris Ellis (Age 63)Chief Operating Officer Dr. Nadege Pelletier Ph.D. (Age 45)Chief Scientific Officer Mr. Graham Griffiths (Age 44)Chief Business Officer Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPGeoffrey LynnSenior Vice President of Synthetic ImmunotherapiesMore ExecutivesKey CompetitorsAnixa BiosciencesNASDAQ:ANIXIO BiotechNASDAQ:IOBTCellectar BiosciencesNASDAQ:CLRBBarinthus BiotherapeuticsNASDAQ:BRNSOramed PharmaceuticalsNASDAQ:ORMPView All CompetitorsInsiders & InstitutionsIpswich Investment Management Co. Inc.Sold 4,000 shares on 1/31/2024Ownership: 0.060%Joseph ScheerenBought 10,000 shares on 6/26/2023Total: $24,400.00 ($2.44/share)Robin WrightBought 13,750 shares on 5/25/2023Total: $36,575.00 ($2.66/share)View All Insider TransactionsView All Institutional Transactions VACC Stock Analysis - Frequently Asked Questions Should I buy or sell Vaccitech stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VACC shares. View VACC analyst ratings or view top-rated stocks. What is Vaccitech's stock price target for 2024? 2 equities research analysts have issued 1-year price objectives for Vaccitech's shares. Their VACC share price targets range from $3.25 to $12.00. On average, they predict the company's stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 205.0% from the stock's current price. View analysts price targets for VACC or view top-rated stocks among Wall Street analysts. How have VACC shares performed in 2024? Vaccitech's stock was trading at $3.69 at the beginning of the year. Since then, VACC shares have decreased by 32.2% and is now trading at $2.50. View the best growth stocks for 2024 here. How were Vaccitech's earnings last quarter? Vaccitech plc (NASDAQ:VACC) announced its earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.25. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $1.65 million. Vaccitech had a negative trailing twelve-month return on equity of 23.41% and a negative net margin of 409.18%. When did Vaccitech IPO? Vaccitech (VACC) raised $110 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. How do I buy shares of Vaccitech? Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VACC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
